Fulcrum Therapeutics, Inc. (FULC): Price and Financial Metrics
FULC Stock Summary
- FULC's went public 1.63 years ago, making it older than merely 2.04% of listed US stocks we're tracking.
- The ratio of debt to operating expenses for Fulcrum Therapeutics Inc is higher than it is for about merely 0.48% of US stocks.
- Revenue growth over the past 12 months for Fulcrum Therapeutics Inc comes in at 220.84%, a number that bests 97.06% of the US stocks we're tracking.
- Stocks that are quantitatively similar to FULC, based on their financial statements, market capitalization, and price volatility, are DTIL, ARDS, NXTC, KALV, and SGMO.
- FULC's SEC filings can be seen here. And to visit Fulcrum Therapeutics Inc's official web site, go to www.fulcrumtx.com.
FULC Stock Price Chart Interactive Chart >
FULC Price/Volume Stats
| Current price | $12.01 | 52-week high | $22.39 |
| Prev. close | $12.50 | 52-week low | $7.01 |
| Day low | $11.81 | Volume | 107,500 |
| Day high | $13.17 | Avg. volume | 161,849 |
| 50-day MA | $12.59 | Dividend yield | N/A |
| 200-day MA | $12.98 | Market Cap | 392.33M |
Fulcrum Therapeutics, Inc. (FULC) Company Bio
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.
Latest FULC News From Around the Web
Below are the latest news stories about Fulcrum Therapeutics Inc that investors may wish to consider to help them evaluate FULC as an investment opportunity.
Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional SharesCAMBRIDGE, Mass., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced closing of its previously announced underwritten public offering of 4,600,000 shares of its common stock at a public offering price of $11.00 per share, which includes 600,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares at the public offering price, less underwriting discounts and commissions. The total gross proceeds of the offering were $50.6 million, before deducting underwriting discounts and commissions and offering expenses payable by Fulcrum. All of the shares in the offering were sold ... |
Fulcrum Therapeutics Announces Pricing of Public Offering of Common StockCAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it has priced an underwritten public offering of 4,000,000 shares of its common stock at a public offering price of $11.00 per share, for total gross proceeds of $44.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Fulcrum. All of the shares in the offering are being sold by Fulcrum. In addition, Fulcrum has granted the underwriters a 30-day option to purchase up to 600,000 additional shares of its common stock at the public offering price, less the underwriting discount and commissions. The offerin... |
Fulcrum Therapeutics to Participate in the H.C. Wainwright BioConnect 2021 ConferenceCAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the virtual H.C. Wainwright BioConnect Conference. A webcast will be available on-demand on Monday, January 11, 2021 at 6:00 a.m. ET through the H.C. Wainwright conference portal and on the Investor Relations section of the Fulcrum website at https://ir.fulcrumtx.com/events-and-presentations. An archived replay will also be available on the Company’s website for 90 days after the conference.About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on imp... |
Is FULC A Good Stock To Buy Now?Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. At Insider Monkey, we follow nearly 817 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are […] |
Fulcrum Therapeutics to Host Virtual Key Opinion Leader Event Featuring FTX-6058 for Sickle Cell DiseaseEvent will review the company’s novel approach to inducing fetal hemoglobin Live webcast on December 15, 2020 at 8:30am ETCAMBRIDGE, Mass., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it will host a Key Opinion Leader (KOL) meeting on Tuesday, December 15, 2020 from 8:30am – 10:00am ET to discuss the company’s program with FTX-6058 for select hemoglobinopathies, including sickle cell disease and beta-thalassemia.Dr. Maureen Achebe and Dr. Gerd Blobel will join senior executives from Fulcrum in presenting and discussing sickle cell disease, the treatment landscape and the FTX-6058 program followed by a Question... |
FULC Price Returns
| 1-mo | 5.17% |
| 3-mo | -4.23% |
| 6-mo | 49.01% |
| 1-year | -31.76% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 2.56% |
| 2020 | -29.63% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Loading social stream, please wait...